POAI Fundamental Analysis - PREDICTIVE ONCOLOGY INC

Name: PREDICTIVE ONCOLOGY INC (POAI) Stock
Brand: PREDICTIVE ONCOLOGY INC
Rating: 2 (3 reviews)

Fundamental Rating

POAI gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 189 industry peers in the Health Care Equipment & Supplies industry. POAI has a bad profitability rating. Also its financial health evaluation is rather negative. POAI is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

POAI had negative earnings in the past year.

POAI had a negative operating cash flow in the past year.

POAI had negative earnings in each of the past 5 years.

POAI had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

POAI has a Return On Assets of -284.62%. This is amonst the worse of the industry: POAI underperforms 95.77% of its industry peers.

		Industry Rank	Sector Rank
ROA	-284.62%
ROE	N/A
ROIC	N/A

ROA(3y)-150.57%

ROA(5y)-139.82%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

POAI has a Gross Margin (48.54%) which is in line with its industry peers.

POAI's Gross Margin has declined in the last couple of years.

The Profit Margin and Operating Margin are not available for POAI so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	48.54%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-9.14%

GM growth 5Y-4.67%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

POAI does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, POAI has more shares outstanding

POAI has more shares outstanding than it did 5 years ago.

There is no outstanding debt for POAI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of -79.56, we must say that POAI is in the distress zone and has some risk of bankruptcy.

POAI's Altman-Z score of -79.56 is on the low side compared to the rest of the industry. POAI is outperformed by 95.24% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-79.56

ROIC/WACCN/A

WACC8.76%

2.3 Liquidity

POAI has a Current Ratio of 0.32. This is a bad value and indicates that POAI is not financially healthy enough and could expect problems in meeting its short term obligations.

POAI has a worse Current ratio (0.32) than 94.71% of its industry peers.

POAI has a Quick Ratio of 0.32. This is a bad value and indicates that POAI is not financially healthy enough and could expect problems in meeting its short term obligations.

The Quick ratio of POAI (0.31) is worse than 94.18% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.32
Quick Ratio	0.31

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 59.02% over the past year.

Looking at the last year, POAI shows a very negative growth in Revenue. The Revenue has decreased by -38.96% in the last year.

Measured over the past years, POAI shows a small growth in Revenue. The Revenue has been growing by 2.86% on average per year.

EPS 1Y (TTM)59.02%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%66.73%

Revenue 1Y (TTM)-38.96%

Revenue growth 3Y4.57%

Revenue growth 5Y2.86%

Sales Q2Q%-99.03%

3.2 Future

Based on estimates for the next years, POAI will show a very strong growth in Earnings Per Share. The EPS will grow by 26.17% on average per year.

The Revenue is expected to grow by 158.10% on average over the next years. This is a very strong growth

EPS Next Y99.58%

EPS Next 2Y41.51%

EPS Next 3Y26.17%

EPS Next 5YN/A

Revenue Next Year569.48%

Revenue Next 2Y232.87%

Revenue Next 3Y158.1%

Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for POAI. In the last year negative earnings were reported.

POAI is valuated quite expensively with a Price/Forward Earnings ratio of 109.31.

POAI's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. POAI is cheaper than 67.20% of the companies in the same industry.

POAI is valuated expensively when we compare the Price/Forward Earnings ratio to 22.55, which is the current average of the S&P500 Index.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	109.31

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

POAI's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.

A more expensive valuation may be justified as POAI's earnings are expected to grow with 26.17% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y41.51%

EPS Next 3Y26.17%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for POAI!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

PREDICTIVE ONCOLOGY INC

NASDAQ:POAI (10/31/2025, 8:08:15 PM)

8.92

+0.46 (+5.44%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Equipment & Supplies

Earnings (Last)08-12 2025-08-12

Earnings (Next)11-10 2025-11-10

Inst Owners1.59%

Inst Owner Change0%

Ins Owners6.32%

Ins Owner Change19.64%

Market Cap46.03M

Revenue(TTM)1.07M

Net Income(TTM)-9777700

Analysts43.33

Price TargetN/A

Short Float %N/A

Short Ratio0.02

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)0

Avg Revenue beat(2)-96.31%

Min Revenue beat(2)-99.82%

Max Revenue beat(2)-92.79%

Revenue beat(4)1

Avg Revenue beat(4)-38.34%

Min Revenue beat(4)-99.82%

Max Revenue beat(4)71.43%

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)0%

EPS NQ rev (3m)0%

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)0%

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	109.31
P/S	43
P/FCF	N/A
P/OCF	N/A
P/B	N/A
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)-20.64

EYN/A

EPS(NY)0.08

Fwd EY0.91%

FCF(TTM)-1.82

FCFYN/A

OCF(TTM)-1.82

OCFYN/A

SpS0.21

BVpS-0.32

TBVpS-0.33

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-284.62%
ROE	N/A
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	48.54%
FCFM	N/A

ROA(3y)-150.57%

ROA(5y)-139.82%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-9.14%

GM growth 5Y-4.67%

F-Score3

Asset Turnover0.31

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	0%
Cap/Sales	0%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	0.32
Quick Ratio	0.31
Altman-Z	-79.56

F-Score3

WACC8.76%

ROIC/WACCN/A

Cap/Depr(3y)20.65%

Cap/Depr(5y)33.78%

Cap/Sales(3y)11.77%

Cap/Sales(5y)26.34%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)59.02%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%66.73%

EPS Next Y99.58%

EPS Next 2Y41.51%

EPS Next 3Y26.17%

EPS Next 5YN/A

Revenue 1Y (TTM)-38.96%

Revenue growth 3Y4.57%

Revenue growth 5Y2.86%

Sales Q2Q%-99.03%

Revenue Next Year569.48%

Revenue Next 2Y232.87%

Revenue Next 3Y158.1%

Revenue Next 5YN/A

EBIT growth 1Y33.36%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y30.15%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y27.34%

OCF growth 3YN/A

OCF growth 5YN/A

PREDICTIVE ONCOLOGY INC / POAI FAQ

What is the ChartMill fundamental rating of PREDICTIVE ONCOLOGY INC (POAI) stock?

ChartMill assigns a fundamental rating of 1 / 10 to POAI.

Can you provide the valuation status for PREDICTIVE ONCOLOGY INC?

ChartMill assigns a valuation rating of 2 / 10 to PREDICTIVE ONCOLOGY INC (POAI). This can be considered as Overvalued.

What is the profitability of POAI stock?

PREDICTIVE ONCOLOGY INC (POAI) has a profitability rating of 0 / 10.

Can you provide the financial health for POAI stock?

The financial health rating of PREDICTIVE ONCOLOGY INC (POAI) is 0 / 10.

PREDICTIVE ONCOLOGY INC (POAI) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

PREDICTIVE ONCOLOGY INC / POAI FAQ

What is the ChartMill fundamental rating of PREDICTIVE ONCOLOGY INC (POAI) stock?

Can you provide the valuation status for PREDICTIVE ONCOLOGY INC?

What is the profitability of POAI stock?

Can you provide the financial health for POAI stock?